13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • ProFound

    Acronym: 

    ProFound

    ACTRN/NCT /ethics: 

    NCT02987543

    Scientific title: 

    A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)

    Summary of trial and patient characteristics

    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase III Tumour Stream Prostate
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Male Anticipated Start Date 2017-02-06
    Molecular Target Anticipated End Date 2021-02-05
    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Male
    Molecular Target
    Tumour Stream Prostate
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date 2017-02-06
    Anticipated End Date 2021-02-05

    Trial Summary

    The purpose of this study is to evaluate the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations.

    Lay Summary

    A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)

    Sponsor / Cooperative group

    Bristol-Myers Squibb

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Nimit Singhal Recruitment on Hold